Loading clinical trials...
Loading clinical trials...
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Administered to at Risk Subjects From 1 to Less Than 18 Years
Conditions
Interventions
Meningococcal vaccine GSK134612
Locations
16
United States
GSK Investigational Site
Antioch, California, United States
GSK Investigational Site
Daly City, California, United States
GSK Investigational Site
Fremont, California, United States
GSK Investigational Site
Hayward, California, United States
GSK Investigational Site
Oakland, California, United States
GSK Investigational Site
Redwood City, California, United States
Start Date
September 10, 2012
Primary Completion Date
October 10, 2014
Completion Date
March 3, 2015
Last Updated
October 18, 2017
NCT04886154
NCT01939158
NCT01266993
NCT02451514
NCT02946385
NCT02639351
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions